Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED), a clinical stage biopharmaceutical company focused on developing novel product candidates to treat brain health disorders, has made significant strides with the announcement of a pricing strategy for its latest offering.
Offering Details
The company disclosed that it will be offering 16,666,667 common shares, with no par value per share, at a price of $6.00 per common share.
In addition to the underwritten offering, MindMed has also entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares, also at a price of $6.00 per common share. Notably, all of the common shares will be sold by MindMed.
The gross proceeds from both the underwritten offering and the concurrent private placement, before deducting underwriting commissions, placement agent fees, and other offering-related expenses, are expected to be approximately $175 million.
Read More: Insiders’ Moves Signal Potential Opportunities in Amtech Systems and Other Penny Stocks
Participation from Investors
The private placement will involve new investors like Deep Track Capital and Commodore Capital, while the underwritten offering will see participation from a range of new investors, including Ally Bridge Group, Driehaus Capital Management, Great Point Partners, LLC, Janus Henderson Investors, Marshall Wace, Octagon Capital, Soleus Capital, Special Situations Funds, Woodline Partners LP, and a leading biotechnology investor associated with one of the largest alternative asset managers.
Underwriters and Placement Agents
Leerink Partners and Cantor are acting as joint bookrunning managers for the underwritten offering and placement agents for the private placement. RBC Capital Markets is serving as the lead manager for the underwritten offering and placement agent for the private placement.
Also Read: Datasea Inc. Makes Headlines with Bold Revenue Forecast
Closing Details
Both the underwritten offering and the concurrent private placement are anticipated to close on or about March 11, 2024, subject to the satisfaction of customary closing conditions.
It’s worth noting that the transactions are not contingent on each other. Importantly, no distribution under the underwritten offering or private placement will occur in Canada or to a person resident in Canada.
Regulatory Compliance
The common shares being offered by the company in the underwritten offering are being done so pursuant to a shelf registration statement on Form S-3 (File No. 333-264648), previously filed with the Securities and Exchange Commission (SEC).
Additionally, a related registration statement was filed with the SEC on March 7, 2024, pursuant to Rule 462(b) under the Securities Act of 1933. These filings, along with a base prospectus dated May 16, 2022, enable the company to proceed with its offering plans.
Key Takeaways
MindMed’s strategic move to raise funds through this offering underscores its commitment to advancing its pipeline of novel product candidates aimed at addressing brain health disorders.
The substantial participation from new investors indicates growing confidence in the company’s vision and potential for future growth.
With a clear pricing strategy and a robust regulatory framework in place, MindMed is poised to leverage the proceeds from this offering to further its clinical development efforts and drive value for shareholders.
Investors and stakeholders alike will be closely monitoring the closing of the offering and subsequent developments as MindMed continues to make strides in the biopharmaceutical space.
DISCLAIMER
You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.
Joel Gbolade is a seasoned financial writer with over seven years of experience in freelance content creation. Specializing in the financial niche and stock market, he has crafted engaging content for numerous websites. His background in technology extends to data processing and computer proficiency, enriching his comprehensive skill set in the financial realm.
